Sarcoidosis

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Retrieved on: 
星期四, 一月 19, 2023
ATyr Pharma, RNA transfection, Pirfenidone, European Patent Office, European Patent Convention, Lung, Biology, Interstitial lung disease, Idiopathic pulmonary fibrosis, Therapy, Patent, ILD, Research, Sarcoidosis, Fibrosis, SAN, Inflammation, EPO, HARS, IPF, N, Pharmaceutical industry

18 787408.6, titled, “Compositions and methods for treating lung inflammation,” covers the use of the company’s lead therapeutic candidate, efzofitimod, in combination with the anti-fibrotic agent pirfenidone.

Key Points: 
  • 18 787408.6, titled, “Compositions and methods for treating lung inflammation,” covers the use of the company’s lead therapeutic candidate, efzofitimod, in combination with the anti-fibrotic agent pirfenidone.
  • A patent from the recently allowed application is expected to be issued in the coming months.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease.

European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis

Retrieved on: 
星期三, 一月 18, 2023
Disease, ATyr Pharma, RNA transfection, NRP2, Inflammation, Prognosis, Union, European Medicines Agency, Royal commission, Death, Quality of life, Committee, Safety, Sarcoidosis, Biomarker, FDA, Scar, Granuloma, Biology, Marketing, COMP, Diagnosis, Patient, Prevalence, Degenerative disease, Research, Neuropilin, Fibrosis, SAN, Medicine, FC, EMA, European Commission, EC, Pharmaceutical industry, EU

“The EC’s decision to grant orphan drug designation to efzofitimod acknowledges the unmet medical need in sarcoidosis for the approximately 150,000 people in the European Union (EU) living with this chronic, debilitating disease,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.

Key Points: 
  • “The EC’s decision to grant orphan drug designation to efzofitimod acknowledges the unmet medical need in sarcoidosis for the approximately 150,000 people in the European Union (EU) living with this chronic, debilitating disease,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
  • “The criteria for orphan status in the EU go beyond the rarity of the disease.
  • Efzofitimod received orphan drug and Fast Track designations for sarcoidosis from the United States Food and Drug Administration (FDA) in 2022.
  • aTyr is currently conducting EFZO-FIT™, a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients.

2022 Hidradenitis Suppurativa (HS) Epidemiology Forecast to 2032: The US has the Largest Number of Affected People - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 16, 2023
Biotechnology, Pharmaceutical, Health, Hidradenitis suppurativa, National Organization for Rare Disorders, Crohn's disease, Groin, Dermis, Epidemiology, Sarcoidosis, Skin, National Organ Transplant Act of 1984, Scar, CD, Squamous cell carcinoma, Diagnosis, Patient, Abscess, Organizing, Biopsy, Health Data Insight, Hidradenitis, Fibrosis, Vaccine, Renewable energy, Dietary supplement, Animal, Medicine, Pharmaceutical industry, HS

The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Among the EU-5 countries, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest cases in 2021.
  • A detailed review of Hidradenitis Suppurativa epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The Hidradenitis Suppurativa Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

Army Captain Le Roy Torres Receives New, Four-Dimensional Lung Scan in Miami

Retrieved on: 
星期四, 一月 12, 2023
Congress, Rhinitis, Prognosis, University, Lung cancer, Autoimmunity, Pulmonary fibrosis, 4D LABS, Address, Sinusitis, Sarcoidosis, FDA, Risk, Degenerative disease, Presidential Medal of Freedom, Lung, Headache, Burn, Blair Brandt, Hope, Smoke, United States Department of Veterans Affairs, Diagnosis, Amnesia, Software, Ventilation, Asthma, XV, Respiratory disease, 4D, COPD, Senior advisor, Army, Veteran, Physician, Medical imaging, Health insurance

MIAMI, Jan. 12, 2023 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, announced that Army Captain Le Roy Torres received a four-dimensional scan using 4D's XV LVAS technology today at the University of Miami Leonard M. Miller School of Medicine. 4DMedical's XV LVAS technology, which received FDA clearance in May 2020, can help physicians accurately detect areas of high and low ventilation in all parts of the lung, during all phases of the breath, with accuracy and without the need for an invasive biopsy.

Key Points: 
  • MIAMI, Jan. 12, 2023 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, announced that Army Captain Le Roy Torres received a four-dimensional scan using 4D's XV LVAS technology today at the University of Miami Leonard M. Miller School of Medicine.
  • His symptoms and those similarly afflicted include shortness of breath, headaches, autoimmune and gastrointestinal issues, memory loss, and toxic brain injury.
  • "My scan today is a major step forward for fellow veterans who are suffering from burn pit exposures and are desperate for answers," said Captain Le Roy Torres.
  • Moving forward, the detailed information provided by the XV LVAS report will help doctors shape and improve Captain Torres' health care options.

EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

Retrieved on: 
星期四, 二月 2, 2023
Cardiovascular disease, CXCR4, Sarcoidosis, Lymphoma, Lausanne University Hospital, Lymphatic system, Muscle tissue, Cardiology, Internal medicine, Diagnosis, Myocarditis, Patient, Leukemia, Research, CHUV, ISS, Nuclear medicine, GMP, Pharmaceutical industry, Medical imaging, Medical device

The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.

Key Points: 
  • The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting.
  • It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a non-cancer indication, opening the way for a broader use of PENTIXAFOR outside of oncology.
  • To investigate the potential of PENTIXAFOR the CHUV will recruit, on its own account, up to 60 patients in a so-called investigator initiated study (ISS).
  • PENTIXAFOR is being developed by Eckert & Ziegler’s subsidiary Pentixapharm GmbH primarily as a superiorly sensitive diagnostic for rare blood cancers, among them myelomas, lymphoma and leukaemia.

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio

Retrieved on: 
星期二, 一月 3, 2023
Internal medicine, IPD, AstraZeneca, Wayne, RNA, Research fellow, Polish Academy of Arts and Sciences, Trinity College, University, Novartis, Biochemistry, Roche, Degenerative disease, AMGEN, Hematology, Sarcoidosis, Immunology, Senior, Publishing, Trinity College Dublin, Book, Publication, Micrometer, CMO, Organic chemistry, Cancer, Eli Lilly, Science, Doctor of Philosophy, Procter, MOC, Novo Nordisk, Research, University of Giessen, Wayne State University, Pharmaceutical industry

WARSAW, Poland, Jan. 3, 2023 /PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces that Dr. Samson Fung, Chief Medical officer has been appointed to the Company's management board. Dr. Adam Gołębiowski has stepped down from the management board to take on the role of Senior Research Fellow at Molecure. In parallel, Dr. Zbigniew Zasłona, has been promoted to Chief Scientific Officer from his current position as VP Research Biology. Dr. Zasłona, will remain on Molecure's management board.

Key Points: 
  • Dr. Adam Gołębiowski has stepped down from the management board to take on the role of Senior Research Fellow at Molecure.
  • In parallel, Dr. Zbigniew Zasłona, has been promoted to Chief Scientific Officer from his current position as VP Research Biology.
  • I am also delighted to announce the promotion of Zbigniew to Chief Scientific Officer, which reflects the significant contribution he has made since joining Molecure.
  • Dr. Adam Gołębiowski has initiated the discovery of both of our clinical stage assets enabling Molecure to become a clinical stage company.

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio

Retrieved on: 
星期二, 一月 3, 2023
Internal medicine, IPD, AstraZeneca, Wayne, RNA, Research fellow, Polish Academy of Arts and Sciences, Trinity College, University, Novartis, Biochemistry, Roche, Degenerative disease, AMGEN, Hematology, Sarcoidosis, Immunology, Senior, Publishing, Trinity College Dublin, Book, Publication, Micrometer, CMO, Organic chemistry, Cancer, Eli Lilly, Science, Doctor of Philosophy, Procter, MOC, Novo Nordisk, Research, University of Giessen, Wayne State University, Pharmaceutical industry

WARSAW, Poland, Jan. 3, 2023 /PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces that Dr. Samson Fung, Chief Medical officer has been appointed to the Company's management board. Dr. Adam Gołębiowski has stepped down from the management board to take on the role of Senior Research Fellow at Molecure. In parallel, Dr. Zbigniew Zasłona, has been promoted to Chief Scientific Officer from his current position as VP Research Biology. Dr. Zasłona, will remain on Molecure's management board.

Key Points: 
  • Dr. Adam Gołębiowski has stepped down from the management board to take on the role of Senior Research Fellow at Molecure.
  • In parallel, Dr. Zbigniew Zasłona, has been promoted to Chief Scientific Officer from his current position as VP Research Biology.
  • I am also delighted to announce the promotion of Zbigniew to Chief Scientific Officer, which reflects the significant contribution he has made since joining Molecure.
  • Dr. Adam Gołębiowski has initiated the discovery of both of our clinical stage assets enabling Molecure to become a clinical stage company.

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

Retrieved on: 
星期一, 十二月 5, 2022
Sarcoidosis, Laboratory, Degenerative disease, Idiopathic pulmonary fibrosis, Cell biology, Flemish Institute for Technological Research, University, Rutgers University, Warsaw Stock Exchange, VIB, Yale University, Patient, ARG1, Cancer, Biology, ARG2, International Institute for Nanotechnology, RNA, MOC, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

Retrieved on: 
星期一, 十二月 5, 2022
Sarcoidosis, Laboratory, Degenerative disease, Idiopathic pulmonary fibrosis, Cell biology, Flemish Institute for Technological Research, University, Rutgers University, Warsaw Stock Exchange, VIB, Yale University, Patient, ARG1, Cancer, Biology, ARG2, International Institute for Nanotechnology, RNA, MOC, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

ISHLT Elects New Board Members and Professional Community Leaders

Retrieved on: 
星期四, 十二月 1, 2022
Consensus, Grant (money), Heart transplantation, International Society, Trainee, Housing, Communities and Local Government Committee, Lung transplantation, Thorax, Snyder, Heart, Associate, MSCE, Chair, Annual, Patient, ABO, Association of Polar Early Career Scientists, Sarcoidosis, COVID-19, Science, FCCP, Care, Executive, Transplant, Interstitial lung disease, Urschel, Embryonic Stem Cell Research Oversight Committees, Research, Medical Microbiology and Immunology, International Society for Heart and Lung Transplantation, MBA, Society, Immunodeficiency, Vaccination, Immunology, Management, Pharmaceutical industry, Dentistry, Pediatrics, IEEE Professional Communication Society, MD

Professor Christian Benden, MD, MBA, FCCP, will serve as ISHLT President-Elect beginning in May 2023 and as ISHLT President beginning in May 2024.

Key Points: 
  • Professor Christian Benden, MD, MBA, FCCP, will serve as ISHLT President-Elect beginning in May 2023 and as ISHLT President beginning in May 2024.
  • "These results represent the development of coordinated election processes and were boosted by a record number of nominations and engagement of professional communities to expand opportunities for leadership in ISHLT to our members.
  • I am also pleased to see ISHLT leaders from five different countries elected to the ISHLT Board of Directors, and to see such a mix of geographical, gender, and generational representation stepping into leadership roles in the Professional Communities."
  • Beginning 1 May, 2023, the new composition of the Board will be:
    Director:Marc de Perrot, MD, Thoracic and Lung Transplant Surgeon, Canada (2024)
    The elected Professional Community leaders are: